Journal article 350 views 46 downloads
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
,
Thinzar Min
Diabetes Therapy, Volume: 11, Issue: 4, Pages: 835 - 844
Swansea University Authors:
Steve Bain , Thinzar Min
-
PDF | Version of Record
Released under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC).
Download (293.61KB)
DOI (Published version): 10.1007/s13300-020-00798-x
Abstract
This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independ...
| Published in: | Diabetes Therapy |
|---|---|
| ISSN: | 1869-6953 1869-6961 |
| Published: |
Springer Science and Business Media LLC
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa53944 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies. |
|---|---|
| Keywords: |
Chronic kidney disease; Diabetesrelated nephropathy; Diabetic nephropathy; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
4 |
| Start Page: |
835 |
| End Page: |
844 |